Clinical trial CLDK378A2303
A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Novartis |
EudraCT Identifier | 2012-005637-36 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01828112 |
Inclusion criteria | Anaplasic lymphoma kinase (ALK) positive |
Last update |